Mid-position treatment strategy for locally advanced lung cancer: a dosimetric study.


Journal

The British journal of radiology
ISSN: 1748-880X
Titre abrégé: Br J Radiol
Pays: England
ID NLM: 0373125

Informations de publication

Date de publication:
Jun 2020
Historique:
pubmed: 16 4 2020
medline: 5 6 2020
entrez: 16 4 2020
Statut: ppublish

Résumé

The internal target volume (ITV) strategy generates larger planning target volumes (PTVs) in locally advanced non-small cell lung cancer (LA-NSCLC) than the Mid-position (Mid-p) strategy. We investigated the benefit of the Mid-p strategy regarding PTV reduction and dose to the organs at risk (OARs). 44 patients with LA-NSCLC were included in a randomized clinical study to compare ITV and Mid-p strategies. GTV were delineated by a physician on maximum intensity projection images and on Mid-p images from four-dimensional CTs. CTVs were obtained by adding 6 mm uniform margin for microscopic extension. CTV to PTV margins were calculated using the van Herk's recipe for setup and delineation errors. For the Mid-p strategy, the mean target motion amplitude was added as a random error. For both strategies, three-dimensional conformal plans delivering 60-66 Gy to PTV were performed. PTVs, dose-volume parameters for OARs (lung, esophagus, heart, spinal cord) were reported and compared. With the Mid-p strategy, the median of volume reduction was 23.5 cm PTV and mean lung dose were significantly reduced using the Mid-p strategy. Delineation uncertainty can unfavorably impact the advantage. To the best of our knowledge, this is the first dosimetric comparison study between ITV and Mid-p strategies for LA-NSCLC.

Identifiants

pubmed: 32293191
doi: 10.1259/bjr.20190692
doi:

Types de publication

Clinical Trial, Phase II Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

20190692

Auteurs

M Ayadi (M)

Radiotherapy and Physics Department, Leon Berard Cancer Center, 28, rue Laennec F-69373, Lyon, France.

T Baudier (T)

Univ Lyon, INSA-Lyon, Université Lyon 1, CNRS, Inserm, Centre Léon Bérard, CREATIS UMR 5220, U1206, F-69373, Lyon, France.

G Bouilhol (G)

Department of Radiotherapy, Hartmann Radiotherapy Center, American Hospital of Paris, Neuilly, France.

P Dupuis (P)

Radiotherapy and Physics Department, Leon Berard Cancer Center, 28, rue Laennec F-69373, Lyon, France.

P Boissard (P)

Radiotherapy and Physics Department, Leon Berard Cancer Center, 28, rue Laennec F-69373, Lyon, France.

R Pinho (R)

Univ Lyon, INSA-Lyon, Université Lyon 1, CNRS, Inserm, Centre Léon Bérard, CREATIS UMR 5220, U1206, F-69373, Lyon, France.

A Krason (A)

Univ Lyon, INSA-Lyon, Université Lyon 1, CNRS, Inserm, Centre Léon Bérard, CREATIS UMR 5220, U1206, F-69373, Lyon, France.

S Rit (S)

Univ Lyon, INSA-Lyon, Université Lyon 1, CNRS, Inserm, Centre Léon Bérard, CREATIS UMR 5220, U1206, F-69373, Lyon, France.

L Claude (L)

Radiotherapy and Physics Department, Leon Berard Cancer Center, 28, rue Laennec F-69373, Lyon, France.

D Sarrut (D)

Univ Lyon, INSA-Lyon, Université Lyon 1, CNRS, Inserm, Centre Léon Bérard, CREATIS UMR 5220, U1206, F-69373, Lyon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH